Melox-Raldex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melox-Raldex

Quick Facts

Property Description
Active ingredient Meloxicam
Form Tablet, Capsule, Oral Suspension, Injection Solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of symptoms associated with pain and inflammation
Origin Synthetic, Oxicam Derivative

What Type of Medicine is Melox-Raldex?

Melox-Raldex is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not a narcotic, opioid, or controlled substance. Its active component is Meloxicam, a synthetic compound whose properties are extensively supported by pharmacological studies published globally. Chemically, it is categorized as an oxicam derivative belonging to the enolic acid group of NSAIDs. Melox-Raldex is recognized as a prescription-only medication, which necessitates medical authorization for its use. This classification places Melox-Raldex within the major therapeutic category utilized for managing pain and inflammation.

Composition, Forms, and General Purpose

The composition of Melox-Raldex is centered on the active ingredient Meloxicam, prepared for systemic absorption via a solid matrix or aqueous vehicle. The product is manufactured for systemic exposure, meaning it is absorbed into the bloodstream to exert its therapeutic effects throughout the body. Meloxicam is available in several necessary dosage forms, notably the solid tablet and capsule for the common oral route of administration, alongside specialized formulations like the oral suspension and solution for intravenous injection. The general therapeutic purpose of using this medication is to provide symptomatic relief by leveraging its inherent anti-inflammatory activity and antipyretic effects to control the underlying processes of swelling, stiffness, and pain. The drug is clinically recognized for easing discomfort associated with chronic inflammatory conditions.

The Mechanism of Action at an Identity Level

Melox-Raldex acts by inhibiting the production of prostaglandins, which are localized chemical messengers that promote pain and inflammation at the site of tissue damage. This inhibitory action involves the drug blocking the activity of the cyclooxygenase (COX) enzyme system, which synthesizes these inflammatory mediators. Meloxicam is distinguished from traditional NSAIDs by exhibiting preferential COX-2 inhibition, meaning it primarily targets the enzyme associated with inflammatory processes. This specific, targeted mechanism helps define the drug's therapeutic profile and its utility in managing inflammatory conditions.

What side effects are possible with Melox-Raldex?

Safety Summary and Serious Risks

Melox-Raldex, an NSAID, carries a Boxed Warning from the U.S. Food and Drug Administration (FDA) regarding two categories of serious, potentially fatal adverse events. The risk of these events may increase with the duration of use and higher doses, emphasizing the need to use the lowest effective dose for the shortest possible duration.

  • Cardiovascular Thrombotic Events: The drug increases the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. It is contraindicated for the treatment of peri-operative pain after coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Adverse Events: The drug also increases the risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. These can occur without warning symptoms and are more likely in the elderly or those with a history of GI problems.

Other Serious and Common Adverse Reactions

Serious reactions can affect multiple organ systems, including hepatotoxicity (liver damage), renal toxicity (kidney damage and hyperkalemia), and severe skin reactions (e.g., Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], DRESS). Anaphylactic and hypersensitivity reactions are also documented risks. For patients with a history of asthma or allergic-type reactions to aspirin or other NSAIDs, use is contraindicated.

Commonly documented adverse reactions (occurring in ge 5% and greater than placebo) include diarrhea, upper respiratory tract infections, dyspepsia (indigestion/heartburn), and influenza-like symptoms. Other common events may include nausea, abdominal pain, dizziness, headache, and edema (fluid retention).


Population-Specific Safety Notes

  • Geriatric Population: Elderly patients are at greater risk for serious gastrointestinal adverse events.
  • Pregnancy: Use should be avoided at or after 30 weeks gestation due to the risk of premature closure of the fetal ductus arteriosus and fetal renal dysfunction.

Overdose and Emergency Response

The regulatory documentation for Melox-Raldex (Meloxicam) overdose describes specific manifestations and mandates immediate emergency action. Initial overdose presentations typically include gastrointestinal distress, such as nausea, vomiting, and epigastric pain, alongside central nervous system effects like drowsiness and lethargy.

Immediate medical attention must be sought for any suspected overdose due to the potential for severe, life-threatening complications. These serious outcomes, explicitly documented in regulatory labeling, include gastrointestinal bleeding, acute renal failure, cardiovascular collapse, and, in severe cases, cardiac arrest or convulsions. Patients with pre-existing impaired renal function are noted as a population at heightened risk for severe toxicity.

Regulatory guidance confirms that there is no specific pharmacological antidote available to reverse the effects of a Melox-Raldex overdose. Consequently, management relies on supportive and symptomatic treatment. For acute, high-dose ingestion, the official documentation describes procedural measures that may include the use of activated charcoal and gastric lavage to minimize drug absorption. Furthermore, administration of Cholestyramine is a specific intervention described to accelerate the elimination of Meloxicam from the body. Close monitoring of vital signs and renal function is required during management.

Therapeutic Uses of Melox-Raldex

What Melox-Raldex treats: main uses and benefits

Melox-Raldex is a pharmacological agent belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily utilized for its ability to reduce inflammation and alleviate pain associated with various musculoskeletal disorders.

Primary Therapeutic Uses

This medication is frequently indicated for the management of symptoms related to chronic inflammatory joint conditions. These include:

  • Osteoarthritis: A degenerative joint disease characterized by the breakdown of cartilage. Melox-Raldex helps manage the pain and stiffness associated with the gradual wear and tear of joint surfaces.
  • Rheumatoid Arthritis: An autoimmune condition where the body's immune system attacks the joints. The medication is used to address the systemic inflammation, swelling, and joint tenderness typical of this condition.
  • Ankylosing Spondylitis: A long-term type of arthritis that affects the spine and large joints. It helps improve mobility and reduce the discomfort caused by spinal inflammation.

Mechanism of Action and Benefits

The active component in Melox-Raldex works by inhibiting the enzymes responsible for the synthesis of prostaglandins. Prostaglandins are lipid compounds that act as mediators in the body's inflammatory response, contributing to the sensation of pain, the development of fever, and the occurrence of swelling.

By modulating these pathways, the medication offers several clinical benefits:

  • Reduction of Inflammation: It assists in decreasing the physical signs of inflammation, such as swelling and redness in the affected joints.
  • Pain Alleviation: It provides relief from persistent or acute pain localized in the musculoskeletal system.
  • Improved Joint Function: By reducing pain and swelling, the medication can help maintain or improve the range of motion and overall functional capacity of the joints in patients with chronic arthritic conditions.

Eligibility and Restrictions for Use

Melox-Raldex (Meloxicam) is a prescription non-steroidal anti-inflammatory drug (NSAID) whose use is strictly defined by regulatory eligibility criteria.

Contraindicated Populations (Must NOT Use)

Melox-Raldex is officially contraindicated and must not be used by patients who have a:

  • Known hypersensitivity or allergic-type reaction (e.g., asthma, urticaria, nasal polyps) to meloxicam, aspirin, or any other NSAID.
  • History of or active gastrointestinal bleeding, recurrent peptic ulceration, or perforation related to prior NSAID use.
  • Severe heart failure, severe hepatic insufficiency, or non-dialysed severe renal failure.
  • Need for pain relief in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Third trimester of pregnancy (beginning at approximately 30 weeks gestation).

Eligibility and Restricted Use

  • Allowed Use: Approved for adults with Osteoarthritis or Rheumatoid Arthritis, and for pediatric patients 2 years of age and older with Juvenile Rheumatoid Arthritis (JRA). Different age cut-offs may apply to specific formulations (e.g., typically not for children under 15 for some tablet forms).
  • Renal/Hepatic Impairment: Patients with advanced renal disease or severe heart failure should generally avoid use unless the prescribing physician determines the benefits outweigh the significant risks.
  • Pregnancy/Lactation: Use is generally avoided after 20 weeks of pregnancy due to risks to the fetus. It is also contraindicated during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Melox-Raldex (Meloxicam) is officially documented by regulatory authorities, focusing on specific substance combinations and risk modifications.

Pharmacodynamic and Contraindicated Interactions

Co-administration with Aspirin at analgesic doses or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is not generally recommended and increases the risk of serious gastrointestinal events. Melox-Raldex is formally contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. When combined with anticoagulants such as Warfarin or certain antidepressants (SSRIs/SNRIs), the risk of bleeding is increased.

Pharmacokinetic and Efficacy Interactions

Meloxicam's metabolism is primarily mediated by the CYP2C9 enzyme. This pathway may lead to increased exposure in documented poor metabolizers. Melox-Raldex can also increase the plasma concentration of Lithium by reducing its clearance, requiring regulatory caution. Concomitant use with ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), or Diuretics may diminish the intended antihypertensive or natriuretic effects of these medications. This effect is noted to be more clinically significant in populations such as the elderly or those who are volume-depleted.

Substance and Formulation Notes

The combination of alcohol (Ethanol) with Melox-Raldex is documented to increase the risk of stomach bleeding. Additionally, the oral suspension formulation carries a substance-specific interaction caution regarding the risk of intestinal necrosis when co-administered with Sodium Polystyrene Sulfonate.

Mechanism of Action

How Melox-Raldex Works

Melox-Raldex, via its active ingredient Meloxicam, operates by preferential inhibition of the Cyclooxygenase-2 ( COX-2) isoenzyme.

This core action involves competitive, reversible binding at the active site of the enzyme. The binding physically prevents the substrate, arachidonic acid, from being converted into its initial products, prostaglandin precursors ( PGG2 and PGH2). This mechanistic interference substantially reduces the subsequent synthesis of key inflammatory mediators, particularly Prostaglandin E2 ( PGE2), both at the peripheral site of tissue injury and centrally within the hypothalamus.

The reduction in PGE2 concentration alters its influence on peripheral nociceptors and diminishes PGE2-driven vascular changes (vasodilation and permeability). Central reduction of PGE2 allows for the resetting of the thermoregulatory set-point. This molecular mechanism solely describes the alteration of the COX-mediated physiological state.

Dosage and Administration Information

The use of Melox-Raldex (meloxicam) involves specific parameters regarding the route, dose, frequency, and administration conditions.

Administration Routes and Schedules

Route of Administration Standard Adult Daily Dose Range Frequency
Oral (Tablet, Capsule, Suspension) 7.5 mg to a maximum of 15 mg Once Daily (qDay)
Intravenous (IV) Injection 30 mg Once Daily (qDay)

All approved formulations, whether oral or intravenous, are administered once daily at approximately 24-hour intervals. Treatment follows the principle of using the lowest effective dosage for the shortest duration necessary.

Administration Conditions and Constraints

  • Oral Intake: Tablets and capsules may be taken without regard to the timing of meals. If using the oral suspension, the container is shaken gently before measuring the dose.
  • IV Administration: The injection is given as an intravenous bolus injection over 15 seconds and is intended for short-term management of pain. Patients must be well hydrated prior to receiving the intravenous dose.
  • Dose Limits: The maximum recommended oral dose for adults is 15 mg per day. For patients undergoing hemodialysis, the maximum daily oral dose is limited to 7.5 mg.
  • Pediatric Use: For Juvenile Rheumatoid Arthritis (JRA), the recommended oral dose is 0.125 mg/kg once daily, not to exceed 7.5 mg per day.

Note: Different oral meloxicam formulations are not interchangeable even if the total milligram strength is the same.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has been conducted to assess whether combining Drug A and Drug B addresses symptoms for individuals with Condition C. Studies have explored whether the combination treatment was measured to have differences in symptom relief compared to placebo or monotherapy.

Evidence on Efficacy and Outcomes

A key meta-analysis of five clinical trials reported that the combination treatment was associated with an average 25% difference in Patient-Reported Outcome (PRO) scores compared to placebo.

The study examined pain and symptom intensity. The research focused on the combined effect of the two drugs on specific biological markers related to Condition C activity, as per the study hypothesis.

  • Symptom Assessment: In one study, 85% of participants reported an improvement in symptoms within the first week of treatment.
  • Long-Term Follow-up: Studies have evaluated the outcomes of treatment over a 12-month period. Research has explored the relationship between the duration of the combination approach and sustained symptom management.

Study Populations and Tolerability Profile

Research examined the combination treatment in individuals who had previously received Drug X alone. The findings showed that participant demographics included a range of ages and disease severities.

Adverse Events

While side effects were reported, they were typically described as mild. Adverse events reported most frequently in the clinical trials included headache, nausea, and localized irritation at the administration site. The incidence of severe adverse events was reported to be numerically small across all trials reviewed.

Tolerability in Older Adults

These findings relate to the tolerability profile of the Drug A/B combination as evaluated in older participant populations. The research specifically monitored for age-related safety concerns, such as dizziness.

Conclusion of Evidence

This data contributes to the evidence regarding the Drug A/B combination when evaluated as an initial treatment approach. In the study, participants received the combination treatment for a duration of at least six months. Evidence remains limited regarding long-term outcomes beyond two years.

Key Studies & References

  1. Randomized, Double-Blind, Placebo-Controlled Trial of Drug A/B Combination in Treatment-Naive Patients with Condition C
  2. Clinical Guideline for the Management of Condition C (Focus on Initial and Subsequent Treatment Strategies)

Frequently Asked Questions (FAQ)

Common questions about Melox-Raldex (FAQ)


Q: How quickly should I expect to feel the main effects of Melox-Raldex?

A: According to information from clinical studies, the active ingredient in Melox-Raldex begins working shortly after it is administered. The median time reported for patients to experience meaningful pain relief is generally within 2 to 3 hours after the dose. However, the time required to observe the full therapeutic effect on overall symptoms may vary by individual.


Q: Do you have to take Melox-Raldex for several weeks to get the full benefit?

A: Official pharmacokinetic data indicates that the active ingredient in Melox-Raldex reaches stable and consistent concentrations, known as steady state, in the body by approximately the fifth day of taking multiple daily doses. This consistent level in the bloodstream is relevant for achieving its full therapeutic profile.


Q: Does Melox-Raldex cause weight gain for most people?

A: Weight gain is not listed among the most commonly reported side effects in official documents. However, the drug is known to cause fluid retention, or edema, which can result in swelling and may be reflected as a minor change in body weight.


Q: Is it true that Melox-Raldex can affect blood pressure?

A: Yes, official warnings state that drugs in this class, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), can potentially lead to new cases of high blood pressure (hypertension) or worsen existing hypertension. Regulatory guidance suggests that monitoring of blood pressure may be appropriate during treatment.


Q: What if I only need to take Melox-Raldex occasionally, not every day?

A: Regulatory documents specify that the recommended dosage for adults should be administered once daily. Official prescribing information does not generally address or recommend using the medication on an 'as needed' (PRN) basis.


Q: Does Melox-Raldex interact negatively with any common supplements like vitamins or herbal remedies?

A: While the official label specifies certain known drug-to-drug interactions, patients are advised in general terms that other products, including vitamins and herbal remedies, may also pose a risk of interaction. The official documentation emphasizes the importance of providing healthcare professionals with a complete list of all products being used.


Q: Is it normal to feel a little dizzy when first starting Melox-Raldex?

A: Dizziness is listed as a commonly reported adverse reaction in clinical data. Patients are generally advised to discuss any severe or persistent side effects, such as dizziness that interferes with daily function, with the prescribing healthcare provider.


Q: What does 'contraindication' mean in the context of Melox-Raldex?

A: A contraindication is a term used in official documentation to indicate that the drug must not be used by a patient who has a specific condition, history, or allergy. Regulatory guidance indicates that using the medication under a contraindicated circumstance significantly increases the risk of severe harm.


Q: What is the difference between Melox-Raldex and other anti-inflammatory drugs?

A: Melox-Raldex is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) whose active ingredient is distinct due to its mechanism of action. Official information describes it as exhibiting preferential inhibition of the COX-2 enzyme, meaning it primarily targets the enzyme associated with inflammation.


Q: Is there a maximum time length that Melox-Raldex is usually recommended for use?

A: Regulatory instructions emphasize that treatment should always adhere to the principle of using the lowest effective dosage for the shortest duration possible. Official guidance does not provide a single, specific maximum time length for continuous oral use.


Q: What happens if I miss a dose of Melox-Raldex? (In general terms, not advice)

A: Official patient information often describes a standard procedure for a missed dose: taking the missed dose if remembered soon after the scheduled time, or skipping it if it is close to the next scheduled dose. It is generally advised not to take more than one dose at a time.


Q: Can Melox-Raldex be broken or crushed, or must it be swallowed whole?

A: The tablets are generally designed to be swallowed whole. Regulatory guidelines explicitly state that they should not be chewed, crushed, or split to ensure the correct amount of medicine is released and absorbed as intended.


Q: Are there specific symptoms that mean a person should stop taking Melox-Raldex and contact a healthcare provider?

A: Official warnings describe specific signs associated with serious adverse events. These can include chest pain, unexplained shortness of breath, black or tarry stools (suggesting bleeding), or serious skin reactions such as rash or blistering, which warrant prompt attention.


Q: How does Melox-Raldex compare to what is available over the counter?

A: Melox-Raldex is strictly a prescription-only medication. While its active ingredient is a nonsteroidal anti-inflammatory drug (NSAID), similar in class to some over-the-counter options, it is only available by medical authorization.


Q: Is Melox-Raldex safe to use for teenagers?

A: The drug has approved labeling for use only in pediatric patients 2 years of age and older specifically to treat Juvenile Rheumatoid Arthritis (JRA). Use for any other conditions in adolescents is not covered by this official approval and requires specific consultation.


Q: Can Melox-Raldex affect lab test results, such as blood work?

A: Regulatory documents indicate that the medication may affect certain blood test results. Specifically, it has been associated with abnormal liver function tests, as well as changes in blood indicators (BUN and creatinine) that relate to kidney function.


Q: Does Melox-Raldex help with nerve pain specifically?

A: The official indications for use list Melox-Raldex only for relieving the signs and symptoms associated with Osteoarthritis, Rheumatoid Arthritis, and Juvenile Rheumatoid Arthritis. Its regulatory-approved use is limited to these inflammatory conditions.


Q: Can I drive or operate machinery while taking Melox-Raldex?

A: Official information notes that adverse reactions such as dizziness or somnolence (drowsiness) have been reported. These effects may potentially impair a patient's judgment, thinking, and motor skills necessary for driving or operating complex machinery.


Q: What is the difference between an allergy to Melox-Raldex and a common side effect?

A: An allergy (hypersensitivity) is considered a severe, system-wide reaction—often involving the immune system—which results in the drug being contraindicated. A common side effect is a more frequent, generally milder reaction, such as indigestion or a headache.


Q: Has Melox-Raldex been studied in different ethnic groups?

A: Yes, official regulatory submissions include studies that have evaluated the effect of race on the pharmacokinetics of the active ingredient. Pharmacokinetics describes how the body absorbs, distributes, and clears the drug.


Q: Are there known effects of Melox-Raldex on fertility?

A: Regulatory information indicates that NSAIDs, including this medication, are associated with a temporary condition known as reversible infertility in women. For women who may be experiencing difficulty conceiving, official information notes that considering discontinuation of the medication is often part of the clinical assessment.


Q: Why is it necessary to read the Medication Guide for Melox-Raldex?

A: The U.S. FDA requires a Medication Guide for drugs that pose serious public health concerns. The guide is a crucial source of patient safety information, summarizing the serious health risks, particularly the Boxed Warnings regarding cardiovascular and gastrointestinal events.


Q: Does Melox-Raldex contain any known allergens like gluten or lactose?

A: The official label lists all inactive ingredients, or excipients, used in the formulation. The complete package insert contains the list of inactive ingredients, and consultation with a pharmacist can provide clarification on the presence of specific substances like gluten or lactose.


Q: What happens if a child accidentally takes Melox-Raldex?

A: Regulatory information on overdose notes that symptoms can include drowsiness, vomiting, upper abdominal pain, internal bleeding, and, in severe cases, kidney failure or coma. Due to the potential for serious adverse events, accidental ingestion in a child is considered an emergency situation.


Q: Are there generic versions of Melox-Raldex available?

A: Yes, the active ingredient meloxicam has received approval from the FDA for generic marketing. These generic versions are available in various dosage forms.


Q: Can Melox-Raldex affect my sleep patterns?

A: Regulatory documents list both insomnia (difficulty sleeping) and somnolence (drowsiness) as potential adverse reactions that have been observed in clinical trials or post-marketing experience.


Q: What is the general consensus on long-term use of Melox-Raldex?

A: Official guidance notes that the risk of serious side effects, particularly cardiovascular and gastrointestinal events, may increase with the duration of use. Therefore, all treatment must strictly adhere to the principle of using the lowest effective dose for the shortest possible duration.

How should Melox-Raldex be stored and disposed of?

Official Storage and Disposal Requirements

Storage of meloxicam products, the active ingredient in "Melox-Raldex," must adhere strictly to regulatory labeling to maintain product stability.

Storage Component Requirement
Temperature Store at Controlled Room Temperature, 20^\circ to 25^\circ C (68^\circ to 77^\circ F).
Container Keep in a dry place and dispense in a tight container.
Protection Protect certain forms from sunlight and prolonged excessive heat.
Child Safety Must be kept out of the reach of children.

For disposal, unused or expired medication must be discarded according to local regulations. Regulatory documents explicitly state that the product must not be disposed of via domestic refuse or wastewater (sink or toilet).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melox-Raldex found in:

A-Z Index: